Vaccine Adjuvant Growth SPI Pharma's QS-21 GH launch and the collaboration with Inimmune indicate a rising vaccine adjuvant platform. This creates sales opportunities with vaccine developers seeking advanced adjuvant systems, formulation support, and reliable access to GMP-compliant manufacturing.

Custom Excipients Suite The company offers highly engineered functional excipients and active ingredients with customized, cost-effective options, backed by a global technical team. This supports cross-sell opportunities for customers aiming to optimize formulations, ensure regulatory compliance, and secure dependable supply chains.

Solid-Dose Innovation S-Tab tablet platform and UltraBurst orally disintegrating tablet capabilities position SPI Pharma as a leader in solid dosage innovations, presenting opportunities to pharma and nutraceutical manufacturers seeking direct compression efficiency and patient-friendly dosage forms.

GMP Compliance Advantage With EXCiPACT GMP certification and strong quality standards, SPI Pharma is a trusted partner for regulated markets, enabling outreach to manufacturers that require audit-ready processes and robust supply chain integrity.

Growth Partnerships Recent acquisitions and partnerships signal growth into digestive health and vaccine-adjuvant domains, opening doors for co-development, private-label opportunities, and long-term supply agreements with GI product lines and vaccine developers.